588 related articles for article (PubMed ID: 26725096)
1. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
[TBL] [Abstract][Full Text] [Related]
3. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
[TBL] [Abstract][Full Text] [Related]
5. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy.
Damodaran O; van Heerden J; Nowak AK; Bynevelt M; McDonald K; Marsh J; Lee G
J Clin Neurosci; 2014 Mar; 21(3):478-81. PubMed ID: 24332268
[TBL] [Abstract][Full Text] [Related]
6. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
7. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
Frandsen J; Orton A; Jensen R; Colman H; Cohen AL; Tward J; Shrieve DC; Suneja G
J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
[TBL] [Abstract][Full Text] [Related]
8. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
[TBL] [Abstract][Full Text] [Related]
9. Gliosarcoma: a clinical study.
Lutterbach J; Guttenberger R; Pagenstecher A
Radiother Oncol; 2001 Oct; 61(1):57-64. PubMed ID: 11578729
[TBL] [Abstract][Full Text] [Related]
10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
11. Treatment and survival of patients harboring histological variants of glioblastoma.
Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and genomic features of gliosarcomas.
Lee D; Kang SY; Suh YL; Jeong JY; Lee JI; Nam DH
J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848
[TBL] [Abstract][Full Text] [Related]
13. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
14. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
16. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
17. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Kiang KM; Chan AA; Leung GK
BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
[TBL] [Abstract][Full Text] [Related]
18. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
